Core A, the Administrative Core of this National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Parkinson's Disease Research Center of Excellence (Udall Center) at the University of Pennsylvania (Penn), will facilitate accomplishing the goals of this multidisciplinary research program. Briefly, the goals of this Udall Center are to elucidate mechanisms of progressive neurodegeneration in Parkinson's disease (PD), especially those mechanisms underlying the cognitive and executive impairments in PD patients without and with dementia (PDD) and in dementia with Lewy bodies (DLB) patients. We hypothesize that disease progression leads to neuron dysfunction and death resulting from the differential transmission of pathologic alpha-synuclein species or strains and their neurotoxic effects in patients with PD/PDD/DLB. Thus, the Aims of Core A are to oversee budgetary and fiscal aspects of this Udall Center;promote and foster interactions between Core and Project investigators, as well as interactions of Udall Center investigators with scientists outside the Center at and beyond Penn;monitor the progress of the Cores and Projects;facilitate the sharing of data, reagents, and resources generated by Penn Udall Center investigators with other researchers in accordance with NIH policies;and participate in annual Udall Center meetings to accelerate the pace of advances in understanding PD/PDD/DLB. By utilizing the strategies in these Aims, Core A will play an important administrative role in this Udall Center by fostering the accomplishment of its overall mission..
Core A is highly relevant to the mission of the Penn Udall Center because it supports the efforts of each of the Cores and Projects in the Center to challenge and re-define current understanding of and research on PD/PDD/DLB by implementing the Specific Aims of Core A.
|Brennan, Laura; Siderowf, Andrew; Rubright, Jonathan D et al. (2016) The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism Relat Disord 25:21-6|
|Fullard, Michelle E; Tran, Baochan; Xie, Sharon X et al. (2016) Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism Relat Disord 25:45-51|
|Roalf, David R; Moore, Tyler M; Wolk, David A et al. (2016) Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease. J Neurol Neurosurg Psychiatry :|
|Brettschneider, J; Irwin, D J; Boluda, S et al. (2016) Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathol Appl Neurobiol :|
|Biundo, Roberta; Weis, L; Bostantjopoulou, S et al. (2016) MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna) 123:431-8|
|Lim, Nicholas S; Swanson, Christine R; Cherng, Hua-Ren et al. (2016) Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol 3:346-55|
|Price, Amy Rose; Peelle, Jonathan E; Bonner, Michael F et al. (2016) Causal Evidence for a Mechanism of Semantic Integration in the Angular Gyrus as Revealed by High-Definition Transcranial Direct Current Stimulation. J Neurosci 36:3829-38|
|Chahine, Lama M; Weintraub, Daniel; Hawkins, Keith A et al. (2016) Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 31:86-94|
|Tuttle, Marcus D; Comellas, Gemma; Nieuwkoop, Andrew J et al. (2016) Solid-state NMR structure of a pathogenic fibril of full-length human Î±-synuclein. Nat Struct Mol Biol 23:409-15|
|White, Matthew T; Shaw, Leslie M; Xie, Sharon X et al. (2016) Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. J Alzheimers Dis 51:463-70|
Showing the most recent 10 out of 250 publications